Skip to main content
Clinical Trials/jRCT2031210566
jRCT2031210566CompletedNot Applicable

Follow ups of patients in AK1830 Phase II Studies

Asahi Kasei Pharma Corporation0 sites10 target enrollmentStarted: February 28, 2022Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10
Primary Endpoint
-

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Single Arm Study
Intervention Model
Single Assignment
Primary Purpose
Other
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
No limit to No limit (—)
Sex
All

Inclusion Criteria

  • Patients who provided written informed consent to participate in the clinical study and who met all of the following criteria
  • [1] Patients who participated in the AK1830 Phase II Study and were deemed to require follow up.
  • [2] Patients who fully understand the contents of the study and are capable of providing informed consent

Exclusion Criteria

  • Patients who met any of the following criteria are to be excluded.
  • [1] Patients who have received their long-term safety outcomes in the AK1830 Phase II Study
  • [2] Patients deemed by the investigator or sub-investigator to be unsuitable for study participation

Outcomes

Primary Outcomes

-

image evaluations

Secondary Outcomes

No secondary outcomes reported

Investigators

Similar Trials